top of page
News, Events and Updates
Search
Anavex Appoints Alzheimer's Industry Leader to Scientific Advisory Board
Dec 3, 2013
Anavex CEO to Participate in Brean Capital 2013 Life Sciences Summit
Nov 21, 2013
Anavex Announces Expansion of Scientific Advisory Board
Nov 20, 2013
Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of AD
Nov 18, 2013
Anavex Announces Positive Data for ANAVEX 2-73 in Alzheimer's Disease
Nov 12, 2013
Blockade of Tau Hyperphosphorylation and Ab1-42 Generation by the Aminotetrahydrofuran Derivative...
Nov 11, 2013
Chronic Treatment with the Tetrahydrofuran Derivative ANAVEX 2-73, a Mixed Muscarinic Cholinergic...
Nov 11, 2013
Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
Nov 7, 2013
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of AD
Nov 4, 2013
Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting
Oct 28, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73
Oct 21, 2013
41
42
43
44
45
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
